Cancer
Samsung invests $110M in healthcare firm GRAIL to expand cancer test into Korea, Asia
The United States-based healthcare firm GRAIL has closed an equity financing deal in which Samsung affiliates, including Samsung C&T Corporation, invested $110 million through the purchase of GRAIL common stock at $70.05 per share.
In Singapore, AI helps cancer patients find clinical trials
Next, the startup is expanding across Southeast Asia.
